Since 2001, NEAR has been at the forefront of developing therapies for Alzheimer's disease. Thanks to the hard work of our scientists and physicians, we are considerably closer to a cure.
However, despite the great progress we have made, there is much work to be done. Our knowledge of the basic processes underlying the initiation and progression of the disease remains incomplete.
The World Alzheimer Report projects that at current rates of growth, the number of people living worldwide with Alzheimer's will grow to over 100 million by 2050. According to the World Health Organization, in the absence of a cure, Alzheimer's disease will soon surpass cancer, AIDS, and all cardiovascular diseases in prevalence.
Despite this worrisome fact, Alzheimer's disease remains significantly underfunded compared to these other diseases. In 2018, the global cost of Alzheimer's is approximately 1 trillion dollars ($1,000,000,000,000) or 5% of the United States GDP. To put matters in perspective, the amount of money spent annually on Alzheimer's research is far less than 1% of the overall costs to society.
Clearly this situation is unsustainable, and charitable foundations cannot survive in a funding vacuum. Due to financial constraints, NEAR has ceased operations and will no longer be accepting donations.
We continue to envision a world without Alzheimer's disease, and encourage the public to contact their elected representatives in order to preserve what limited medical research funding remains. The US needs to dramatically increase funding for Alzheimer's research by at least ten-fold, if we hope to find a cure in our lifetimes. With your support, biomedical researchers will continue the mission to eradicate Alzheimer's disease.